<DOC>
	<DOCNO>NCT01504178</DOCNO>
	<brief_summary>Patients suffer Parkinson 's disease ( PD ) frequently experience painful sensation could , part , due central modification nociception mechanism . Previous study show pain perception alter Parkinson 's disease ( subjective objective pain threshold pain-induced cerebral activity ) administration L-Dopa normalized alteration . In central nervous system , L-Dopa convert dopamine norepinephrine . Apomorphine ( dopamine agonist ) effect pain threshold pain-induced cerebral activity . Therefore noradrenergic system could involve pain alteration PD . To assess role noradrenergic system pain patient PD , choose duloxetine ( norepinephrine serotonin reuptake inhibitor ) recent study show duloxetine allow improvement pain clinical score ( pain questionnaire ) patient PD . 36 patient enrol study . We suppose chronic intake duloxetine increase pain perception level compare placebo . This increase would observe L-Dopa .</brief_summary>
	<brief_title>Evaluation Role Noradrenergic System Pain Perception Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Patients clinical diagnosis Parkinson 's disease accord criterion UKPDSBB Parkinson 's disease patient score ≤ 3 Hoehn Yahr scale Patients treat dopaminergic antiparkinsonian drug ( LDopa , dopamine agonist , ICOMT… ) Patients affiliate social protection program Women efficacy contraception Patients suffer another pathology cause chronic pain ( rheumatic disease , traumatic orthopedic pathologies… ) Parkinson 's disease patient score &gt; 3 Hoehn Yahr scale Depressed patient ( MADRS score &lt; 16 ) Patients suffer cancer Patients tutelage , curatella law protection Patients complete contraindication apomorphine injection duloxetine administration ( selective serotonin reuptake inhibitor monoamine oxydase inhibitor ) Patients without control arterial hypertension Patients neuroleptic treatment Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Noradrenergic system pain Parkinson 's disease</keyword>
</DOC>